WO2023146971A1 - Dispositif d'administration d'un composé dans des régions précises de la cavité nasale - Google Patents

Dispositif d'administration d'un composé dans des régions précises de la cavité nasale Download PDF

Info

Publication number
WO2023146971A1
WO2023146971A1 PCT/US2023/011634 US2023011634W WO2023146971A1 WO 2023146971 A1 WO2023146971 A1 WO 2023146971A1 US 2023011634 W US2023011634 W US 2023011634W WO 2023146971 A1 WO2023146971 A1 WO 2023146971A1
Authority
WO
WIPO (PCT)
Prior art keywords
delivery tube
delivery
medicament
fluid conduit
flexible fluid
Prior art date
Application number
PCT/US2023/011634
Other languages
English (en)
Inventor
Andrew Robert COOPER
Richard Brewer
Barzin GAVTASH
Hendrik VERSTEEG
Original Assignee
Kindeva Drug Delivery L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindeva Drug Delivery L.P. filed Critical Kindeva Drug Delivery L.P.
Publication of WO2023146971A1 publication Critical patent/WO2023146971A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Definitions

  • the present disclosure relates to a device for delivery of a compound to at least one specific region of the nasal cavity. More specifically, the present disclosure relates to a nasal pressurised metered dose delivery device for delivering medicaments (also known as active pharmaceutical ingredients, or APIs) to one or more of the olfactory region, the turbinates region and the nasopharynx of the nasal cavity.
  • medicaments also known as active pharmaceutical ingredients, or APIs
  • Examples of specific regions in the nasal cavity that may benefit from local, targeted application of medicaments are the olfactory region, the turbinates (superior, middle and / or inferior) and the nasopharynx.
  • BBB blood-brain barrier
  • the olfactory nerve extends from the brain into the nasal cavity where direct contact is made between these nerves and the cavity, penetrating the mucosal lining. Millions of neurons are present at this location, facilitating the subject's sense of smell. It has been suggested that these neurons may offer a route to deliver medicaments from the nasal cavity to the brain (the ‘nose-to-brain ! or ! N2B ! route). Importantly, use of this route would bypass the otherwise prohibitive blood-brain barrier. Nose to brain transport is therefore seen as an important potential route to deliver important drugs to the CNS.
  • the olfactory nerve endings offer this potential, they are still not easily accessed. They are positioned well into, and on the superior surface of, the nasal cavity. The region is situated in an area of complex and narrow geometry. Therefore, there are challenges in designing a mechanism to deliver medicaments to this surface.
  • the nasopharynx is the uppermost part of the throat, lying above the oral cavity, extending after the choanae in the nasal cavities. It will be noted that the nasopharynx is described herein as part of the nasal cavity.
  • Targeted nasopharynx drug delivery has potential for therapies for both cancer and viruses located in this region e.g., the Covid-19 virus (SARS-CoV-2).
  • SARS-CoV-2 the Covid-19 virus
  • Applicant’s co-pending application PCT/US2021/043424 describes a nasal delivery device for delivery of a medicament to the olfactory, turbinates and nasopharyngeal regions.
  • the device disclosed therein relies on increasing the delivery force of the medicament in order to project further into the nasal cavity towards the desired location.
  • EP 0 692 273 discloses a nebulizing catheter arrangement in which an endotracheal tube is used to feed a catheter into a patient’s lungs. Liquid medication is mixed with gas to aerosolise and propel the medicament to the lungs. In this situation, the patient is intubated and a ventilator is attached to the endotracheal tube.
  • US 5,062,423 discloses a device for delivery of an aerosolised drug for treatment of lung conditions such as asthma to an animal.
  • a canister containing a medicament and a propellant is provided with a metering valve for dispensing a dose of medicament.
  • a nasai tube is inserted into the nostril in order to deliver the medicament to the nasal-pharyngeal cavity of the animal whereby it has a better chance of reaching the animal’s lungs.
  • US 2006/276,552 discloses a nasal catheter intended to be placed through the patient’s nostrils and extend through the nasal cavity to the nasopharyngeal region.
  • CN106994205A discloses a medical device for the nasopharynx having an atomiser at one end.
  • CN111388848A discloses a drug delivery device and method for delivery to the nasopharynx.
  • the device comprises a C-shaped nozzle for insertion into the nasal cavity.
  • a device for delivery of a medicament to a target region including a canister that includes a container containing a pressurised propellant and the medicament; and a metering valve configured to release a predetermined amount of the pressurised propellant and the medicament.
  • the device further includes an actuator including a valve block receiving the metering valve, the valve block defining a chamber for passage of propellant and medicament expelled from the canister; and a delivery tube for insertion into a user’s nostril.
  • the delivery tube includes an elongate, flexible fluid conduit in fluid communication with the valve block, the flexible fluid conduit defining at least one delivery opening for delivery of the medicament to the inside of a human or animal nasal cavity in use.
  • the delivery tube further includes a positioning element attached to the flexible fluid conduit, where the positioning element is configured to cause a deformation in the flexible fluid conduit to direct the delivery opening at the target region.
  • the provision of the combination of a flexible tube and positioning element allows the delivery opening to be positioned very accurately within the nasal cavity to target specific areas.
  • the positioning element is a mass element positioned distal to the valve block, configured to produce a curvature in the delivery tube in use by virtue of its weight acting on the delivery tube.
  • the mass element is at least partially constructed from a material having a higher density than the material from which the delivery tube is constructed.
  • the mass element may be a region of increased volume of material having a similar, or the same density as the delivery tube material. For example, a region of increased cross-sectional area.
  • the positioning element is a bulbous element extending outwardly from the delivery tube, configured to guide and thereby deform the delivery tube within the nasal cavity.
  • the bulbous element guides the delivery tube by contacting an internal surface of the user’s nasal cavity.
  • the positioning element may be a combined mass and bulbous element.
  • bulbous element we mean that the element has an outer perimeter having an area greater than the bulk of the delivery tube and preferably at least twice the diameter (or equivalent diameter) of the delivery tube.
  • the positioning element is annular in shape, surrounding the delivery tube.
  • the delivery tube and the positioning element may be unitary.
  • the delivery tube has a point where it emerges from, or joins the actuator, and a free end.
  • the distance between these points is referred to as the ‘free length’.
  • the positioning element is positioned at least partially in the 50% of the free length adjacent the free end. More preferably, the positioning element is positioned at least partially in the 20% of the free length adjacent the free end. Even more preferably, the positioning element is positioned at least partially in the 10% of the free length adjacent the free end.
  • the positioning element may be configured to apply a deflection force between two spaced apart positions on the delivery tube to thereby deform the delivery tube.
  • the deflection force may be, e.g., tensile or compressive.
  • the positioning element may provide this force by provision of an elastic deformation element to urge the tube into a curved shape.
  • the delivery tube and the positioning element are unitary.
  • the actuator includes a nosepiece base extending therefrom, where the delivery tube extends from the nosepiece base.
  • the delivery tube may extend from the valve block, through the nosepiece base.
  • the nosepiece base has a higher stiffness than a portion of the delivery tube extending from the nosepiece base such that the nosepiece base does not deform in use.
  • the actuator has a primary axis, and where the nosepiece base has a flow axis extending at an angle to the primary axis, where the angle is greater than 15 degrees and less than 75 degrees.
  • the delivery tube extends into the nosepiece base towards the valve block.
  • the delivery tube has a length of between 30 and 120 mm from the actuator.
  • the elongate, flexible fluid conduit includes a lumen having a cross sectional area which is between 0.3 and 10 mm 2 .
  • the lumen may be of variable cross sectional area, tapering from one size to another, inwardly or outwardly.
  • the elongate, flexible fluid conduit is constructed from a material having a Youngs modulus below 10GPa, preferably between 0.01 and 10 GPa.
  • the bending stiffness of the delivery tube is less than 0.1N/mm, and more preferably between 0.005 and 0.1 N/mm at the free end.
  • the material is PEEK.
  • the at least one delivery opening includes an opening in an axial end of the delivery tube.
  • the at least one delivery opening includes an opening in a sidewall of the delivery tube.
  • the device may include one or more positioning elements as required.
  • the device may include one delivery opening or multiple adjacent delivery openings.
  • a method of delivery of a medicament to at least one of the olfactory region, the turbinates region and the nasopharynx of a nasal cavity includes providing a canister that includes a container containing a pressurised propellant and the medicament, and a metering valve configured to release a predetermined amount of the pressurised propellant and the medicament.
  • the method further includes providing an actuator that includes a valve block receiving the metering valve, the valve block defining a chamber for passage of propellant and medicament expelled from the canister.
  • the method further includes providing a delivery tube for insertion into a user’s nostril, the delivery tube includes an elongate, flexible fluid conduit in fluid communication with the valve block, the flexible fluid conduit defining a delivery opening where the delivery tube includes a positioning element attached to the flexible fluid conduit.
  • the method further includes inserting the elongate, flexible fluid conduit into a nasal cavity of a human or animal such that the positioning element produces curvature in the flexible fluid conduit; and actuating the metering valve to deliver the medicament to the inside of the nasal cavity.
  • a device for delivery of a medicament to at least one of the olfactory region, the turbinates region and the nasopharynx of a nasal cavity includes a canister including a container containing a pressurised propellant and the medicament; and a metering valve configured to release a predetermined amount of the pressurised propellant and the medicament.
  • the device further includes an actuator including a valve block receiving the metering valve, the valve block defining a chamber for passage of propellant and medicament expelled from the canister; and a delivery tube for insertion into a user’s nostril.
  • the delivery tube includes an elongate, flexible fluid conduit in fluid communication with the valve block, the flexible fluid conduit defining at least one delivery opening for delivery of the medicament to the inside of a human or animal nasal cavity in use.
  • the delivery tube includes an elbow portion having an angle of between 20 and 160 degrees to the delivery tube to direct the delivery opening towards a targeted area in use.
  • the actuator includes a nosepiece base extending therefrom, where the delivery tube extends from the nosepiece base.
  • the nosepiece base has a higher stiffness than the delivery tube such that the nosepiece base does not deform in use.
  • the actuator has a primary axis, and where the nosepiece base has a flow axis extending at an angle to the primary axis, where the angle is greater than 15 degrees and less than 75 degrees.
  • the delivery tube extends into the nosepiece base towards the valve block.
  • the delivery tube has a length of between 30 and 120 mm from the actuator.
  • the elongate, flexible fluid conduit includes a lumen having a cross sectional area which is between 0.3 and 10 mm 2 .
  • the elongate, flexible fluid conduit is constructed from a material having a Youngs modulus below 10GPa, preferably between 0.01 and 10 GPa.
  • the material is PEEK.
  • a method of deiivery of a medicament to a target region the target region being at least one of the olfactory region, the turbinates region and the nasopharynx of a nasal cavity.
  • the method includes providing a canister that includes a container containing a pressurised propellant and the medicament; and a metering valve configured to release a predetermined amount of the pressurised propellant and the medicament.
  • the method further includes providing an actuator that includes a valve block receiving the metering valve, the valve block defining a chamber for passage of propellant and medicament expelled from the canister.
  • the method further includes providing a delivery tube for insertion into a user’s nostril, the delivery tube including an elongate, flexible fluid conduit in fluid communication with the valve block, the flexible fluid conduit defining a delivery opening where the delivery tube includes an elbow portion having an angle of between 20 and 160 degrees to the delivery tube to direct the delivery opening towards the target region in use.
  • the method further includes inserting the elongate, flexible fluid conduit into a nasal cavity of a human or animal such that the positioning element produces a curvature in the flexible fluid conduit; and actuating the metering valve to deliver the medicament to the inside of the nasal cavity.
  • the term “about” refers to that variation in the measured quantity as would be expected by the skilled artisan making the measurement and exercising a level of care commensurate with the objective of the measurement and the precision of the measuring equipment used.
  • “up to” a number includes the number (e.g., 50).
  • FIGURE 1 is a side section view of a first device in accordance with the present disclosure
  • FIGURE 2 is a side section view of the device of Figure 1 in-use in a user’s nasal cavity;
  • FIGURE 3 is a side section view of a second device in accordance with the present disclosure in-use in a user’s nasal cavity;
  • FIGURE 4 is a side section view of a third device in accordance with the present disclosure in-use in a user’s nasal cavity;
  • FIGURE 5 is a side section view of a fourth device in accordance with the present disclosure in-use in a user’s nasal cavity;
  • FIGURE 6 is a side section view of a fifth device in accordance with the present disclosure in- use in a user’s nasal cavity
  • FIGURE 7 is a side section view of a sixth device in accordance with the present disclosure in-use in a users nasal cavity;
  • FIGURE 8 is a side section view of a seventh device in accordance with the present disclosure in-use in a users nasal cavity.
  • FIGURE 9 is a side section view of an eighth device in accordance with the present disclosure in-use in a user's nasal cavity.
  • Figure 2 onwards there is shown a cross-section through a human head.
  • the crosssection shows the nose 10; nostril 12; nasal cavity 13 including nasal vestibule 14, olfactory region 16, superior turbinate 18, middle turbinate 20, the inferior turbinate 22; and the nasopharynx 24, leading to the pharynx 26.
  • pMDDs pressurised metered delivery devices
  • pMDIs pressurised metered dose inhalers
  • a device 100 in the form of a nasal pMDI is shown.
  • the device 100 can be configured to deliver a medicament to a target region such as at least one of the olfactory region 16, the turbinates region 18, 20, 22, or the nasopharynx 24 of the nasal cavity 13.
  • the device 100 includes a valved canister 102 and an actuator 104.
  • the canister 102 includes a container 106 defining a base 108. At the opposite end of the base 108 there is provided a metering valve 110.
  • the valve 110 is sealed to the container 106 via a crimp 112.
  • the valve 110 includes a valve stem 114 which is resiliently moveable towards the container 106. Upon depression of the valve stem 114 towards the container 106, the metering valve 110 is configured to release a predetermined (metered) amount or volume of container fluid content from a valve orifice.
  • Such valves are well known in the art.
  • the canister 102 is primarily constructed from a metal material (aluminium in this embodiment), although parts of the valve 110 are constructed from plastics materials, as is known in the art. Various coatings can be present on the internal surface of the canister 102 as known in the art.
  • the container 106 contains a mixture of a propellant and a medicament formulation.
  • the actuator 104 includes a housing 116, a valve block 118 and a delivery arrangement 120.
  • the housing 116 includes a generally cylindrical canister-receiving portion 122 having an open end 124 and a closed end or base 126.
  • a nosepiece base 152 Projecting radially outwardly from the cylindrical portion 122 and angled from the base 126 upwardly in the general direction of the open end 124 (i.e. , projecting both radially and axially) is a nosepiece base 152.
  • the nosepiece base 152 has a first end 134 in communication with the cylindrical portion 122 and a second, free end 136.
  • the valve block 118 is a unitary body defining an inlet 138 defining a valve stem receiving recess 140 having a shoulder 142.
  • the valve block 118 can define an axial flow channel or chamber 144 for passage of propellant and medicament expelled from the canister 102.
  • the recess 140 is in communication with the axial flow channel or chamber 144. Adjacent the flow channel 144 and in communication therewith, extending to a sidewall of the valve block 118 there is provided an exit opening 148.
  • the delivery arrangement 120 includes the nosepiece base 152 and a delivery tube 154.
  • the nosepiece base 152 is elongate having an end portion 153 that is frustoconical in shape tapering from a wider first end 166 to a narrower second end 168.
  • the nosepiece base 152 defines a through bore or lumen 170 defining a delivery tube opening 176 at the second end 168.
  • the through bore 170 is in fluid communication with the exit opening 148 of the valve block 118.
  • the nosepiece base 152 can have a flow axis that extends along the through bore 170.
  • the through bore or lumen 170 can have any suitable cross- sectional area. In one or more embodiments, the through bore or lumen 170 can have a cross section area that is between 0.1 and 10 mm 2 .
  • the actuator has a primary axis along the flow channel or chamber 144, where the flow axis of the nosepiece base 152 extends at an angle to the primary axis of the actuator. In one or more embodiments, the angle between the flow axis and the primary axis is greater than 15 degrees and less than 75 degrees.
  • the device 100 includes a delivery tube 154 for insertion into a user’s nostril 12.
  • the delivery tube 154 is an elongate, flexible fluid conduit that is in fluid communication with the valve block 118. Further, the delivery tube 154 can include a constant cross section and have a through bore 178.
  • the delivery tube 154 has an entry inlet 180 and a delivery outlet or opening 182 for delivery of the medicament to the inside of a human or animal nasal cavity 13.
  • the delivery tube 154 is constructed from a flexible, elastically deformable material, i.e., the Young’s modulus of the material is typically between 0.01 GPa and 10 GPa.
  • Exemplary materials include, e.g., PEEK (Polyether ether ketone) having a Young’s modulus of 3.6GPa.
  • the nosepiece base 152 has a higher stiffness than the delivery tube 154 such that the nosepiece based does not deform in use.
  • the delivery tube 154 can also include a positioning element attached to the delivery tube (i.e., flexible fluid conduit) that is configured to cause a deformation in the tube to direct the delivery outlet or opening 182 at the target region.
  • a positioning element attached to the delivery tube (i.e., flexible fluid conduit) that is configured to cause a deformation in the tube to direct the delivery outlet or opening 182 at the target region.
  • a positioning element that includes a mass element 184.
  • the mass element 184 is positioned distal to the valve block 118 and is configured to produce a curvature in the delivery tube 154 in use by virtue of its weight acting on the deliver tube.
  • the mass element 184 is attached to the delivery tube 154 and due to its location proximate the delivery outlet 182, and the fact that the inlet 180 end of the delivery tube is held in the nosepiece base 152, it elastically deforms the delivery tube to form a curved shape.
  • the delivery tube 154 effectively forms a cantilevered beam having a built-in end.
  • the mass element 184 in this embodiment is an annular component surrounding the tube 154 and can be constructed from a soft but relatively dense elastomeric material such as rubber. In one or more embodiments, the mass element 184 is at least partially constructed from a material having a higher density than the material from which the delivery tube 154 is constructed.
  • proximate the end we mean that the mass element 184 is at least partially located within 10% of the free end 186 of the delivery tube 154. For example, if the delivery tube 154 is 10 cm long, at least some of the mass element 184 is located with 1 cm of the free end 186 of the delivery tube.
  • the end of the delivery tube 154 is fed into the user’s nostril 12.
  • the tube 154 continues to be fed into the nasal cavity 13 by bringing the nosepiece base 152 into contact, and engagement with the nostril 12.
  • the mass element 184 causes a downwardly concave (upwardly convex) curvature of the tube 154 such that the delivery outlet 182 is directed towards the user’s nasopharynx 24.
  • a second embodiment of a device 200 is shown.
  • the device 200 is similar to the device 100 with similar features numbered 200 or greater.
  • a delivery tube 254 of the device 200 is shorter than delivery tube 154, having an inlet 280 and delivery outlet or opening 282 joined by a through bore 278.
  • a positioning element that is a bulbous element 284 is positioned proximate the outlet 282.
  • the bulbous element 284 has a cross-section greater than that of the tube 254.
  • the bulbous element 284 positions the end of the tube 254 in the nasal cavity by bearing against one or more sidewalls of the nasal cavity. This ensures that the outlet 282 is directed towards the olfactory region 16.
  • the bulbous element 284 is configured to guide and thereby deform the delivery tube 254 within the nasal cavity 13.
  • a third embodiment of a device 300 is shown.
  • the device 300 is similar to the device 100 with similar features numbered 300 or greater.
  • a free end 386 of a delivery tube 354 is closed, and instead a delivery outlet or opening 382 is formed from a plurality of radially extending openings 383 in fluid communication with a through bore 378.
  • a positioning element that is a bulbous element 384 is positioned proximate the outlet 382.
  • the bulbous element 384 has a cross-section greater than that of the tube 354.
  • the bulbous element 384 positions the end of the tube 354 in the nasal cavity by bearing against one or more sidewalls of the nasal cavity. This ensures that the outlet 382 Is directed towards the olfactory region 16, i.e., that the tube 354 is substantially parallel to the upper surface of the nasal cavity 13.
  • the medicament Upon activation of the pMDI device 300, the medicament exits the tube 354 via the openings 383 to form a spray, depositing the medicament evenly over the olfactory region 16.
  • a fourth embodiment of a device 400 is shown.
  • the device 400 is similar to the device 100 with similar features numbered 400 or greater.
  • a positioning element that is a mass element 484 is positioned midway along a tube 454.
  • the mass element 484 in this embodiment is an annular component surrounding the tube 454, constructed from a soft elastomeric material such as rubber.
  • the mass element 484 is dimensioned to keep the tube 454 away from the superior and inferior internal walls of the nasal cavity 13.
  • the medicament is delivered via delivery outlet or opening 482, although it will be understood that it could be delivered via one or more spray orifices in the wall of the tube per the third embodiment.
  • a fifth embodiment of a device 500 is shown.
  • the device 500 is similar to the device 100 with similar features numbered 500 or greater.
  • a positioning element that is a mass element 584 is positioned at a free end 586 of a shorter tube 554, which only extends as far as the turbinates region 20 of the nasal cavity 13 where it terminated.
  • the mass element 584 in this embodiment is an annular component surrounding the tube 554, constructed from a soft elastomeric material such as rubber.
  • a delivery outlet or opening 582 is formed from a plurality of radially extending openings 583 in fluid communication with a through bore 578.
  • a sixth embodiment of a device 600 is shown.
  • the device 600 is similar to the device 100 with similar features numbered 600 or greater.
  • a tube 654 has an end section 685 that is connected to the tube via a kink or elbow 687 such that a delivery outlet or opening 682 is directed towards the region of interestTM-in this case the olfactory region 16.
  • a seventh embodiment of a device 700 is shown.
  • the device 700 is similar to the device 100 with similar features numbered 700 or greater.
  • a tube 754 has no mass or bulbous element. Instead, the tube 754 is deformed via a positioning element that is a tension member 790 that connects two spaced-apart positions 702, 704 on the tube 754.
  • the tension member 790 is constructed from a flexible, resilient material having a resting (unstressed) length less than that of the tube 754. in this way, the tension member 790 tends to puli the tube 754 into a curved shape as shown in Figure 8.
  • the tension member 790 is configured to apply a deflection force between the two spaced-part positions 702, 704 on the delivery tube 754 to thereby deform the delivery tube.
  • the tension member 790 is an elastically deformable element configured to urge the delivery tube 754 into a curved shape.
  • the length and material of the tension member 790 is selected such that the tube 754 can easily be straightened by hand for insertion into the nose 10, at which point it will adopt its curved form within the nasal cavity 13. It will be noted that in this embodiment, a delivery outlet or opening 782 of the tube 754 is directed towards the nasopharynx 24.
  • FIG. 9 an eighth embodiment of a device 800 is shown.
  • the device 800 is similar to the device 100 with similar features numbered 800 or greater, in this embodiment a tube 854 has no mass or bulbous element. Instead, the tube 854 is deformed via a shape memory member 890 that is connected to the upper surface of the tube 854.
  • the member 890 is constructed from a flexible, resilient material having a resting (unstressed) shape being curved per Figure 8. In this way, the member 890 tends to form the tube 854 into a curved shape as shown in Figure 8.
  • the material of the member 890 is selected such that the tube 854 can easily be straightened by hand for insertion into the nose 10, at which point it will adopt its curved form within the nasal cavity 13. It will be noted that in this embodiment, a delivery outlet or opening 882 of the tube 854 is directed towards the nasopharynx 24. Variations
  • the mass element Is described as a separate component that is attached to the tube, it may alternatively be co-moulded therewith.
  • the mass element may include one or more components that have been overmoulded proximate the end of the tube.
  • the mass element may simply be an area of increased cross section of the tube material.
  • the bulbous element may be constructed from the same material as the tube, and may be fluid filled, with a liquid e.g., water, or a gas, e.g., with air.
  • the mass element and bulbous element may be combined and / or interchanged.
  • the benefit of the mass element is providing deformation of the tube via application of a force, in the form of weight.
  • the benefit of the bulbous element is positioning of the tube by contact with internal surfaces of the nasal cavity. Therefore, a bulbous mass element may be provided that has both of these benefits.
  • the tension applied by the member 790 in Figure 8 is applied by the inherent elasticity of the member. Instead, it may be provided by a mechanism designed to pull the member. In this case, the member 790 would be inextensible.
  • the delivery tube may be constructed from multiple materials, for example, several lengths of materials having different properties. This may be used to influence the deformed shape of the tube.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif (100) d'administration d'un médicament. Le dispositif comprend une cartouche (102) qui comprend un récipient contenant un agent propulseur sous pression et le médicament ; et une valve doseuse configurée pour libérer une quantité prédéterminée de l'agent propulseur sous pression et du médicament. Le dispositif (100) comprend en outre un actionneur (104) qui comprend un bloc de soupape recevant la soupape de dosage, le bloc de distribution définissant une chambre pour le passage de l'agent propulseur et du médicament expulsé de la cartouche ; et un tube d'administration pour l'insertion dans la narine d'un utilisateur. Le tube d'administration comprend un conduit de fluide allongé et flexible en communication fluidique avec le bloc de distribution, le conduit de fluide flexible définissant au moins une ouverture d'administration pour l'administration du médicament à l'intérieur d'une cavité nasale humaine ou animale lors de l'utilisation. Le tube de distribution comprend un élément de positionnement (184) fixé au conduit de fluide flexible.
PCT/US2023/011634 2022-01-28 2023-01-26 Dispositif d'administration d'un composé dans des régions précises de la cavité nasale WO2023146971A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2201107.6A GB202201107D0 (en) 2022-01-28 2022-01-28 Device for delivery of a compound to specific regions of the nasal cavity
GB2201107.6 2022-01-28

Publications (1)

Publication Number Publication Date
WO2023146971A1 true WO2023146971A1 (fr) 2023-08-03

Family

ID=80621225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/011634 WO2023146971A1 (fr) 2022-01-28 2023-01-26 Dispositif d'administration d'un composé dans des régions précises de la cavité nasale

Country Status (2)

Country Link
GB (1) GB202201107D0 (fr)
WO (1) WO2023146971A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5062423A (en) 1990-02-27 1991-11-05 Minnesota Mining And Manufacturing Company Equine aerosol drug delivery method and apparatus
EP0692273A1 (fr) 1994-06-17 1996-01-17 Trudell Medical Limited Cathéter comprenant un dispositif de nébulisation et son procédé de fabrication
WO2003000310A2 (fr) * 2001-06-12 2003-01-03 Optinose As Dispositifs d'administration nasale
US20060276552A1 (en) 2005-05-13 2006-12-07 Denise Barbut Methods and devices for non-invasive cerebral and systemic cooling
WO2012123819A1 (fr) * 2011-03-15 2012-09-20 Optinose As Et Al Administration nasale
EP3139985A1 (fr) * 2014-05-09 2017-03-15 Norton (Waterford) Limited Dispositif d'aérosol
CN106994205A (zh) 2017-04-13 2017-08-01 杜云飞 一种多功能鼻咽医用装置
CN111388848A (zh) 2020-03-26 2020-07-10 乐恩(北京)医药技术有限公司 一种鼻咽部给药器和给药方法
WO2020197995A1 (fr) * 2019-03-28 2020-10-01 The Board Of Trustees Of The Leland Stanford Junior University Système d'administration par voie nasale de médicament
WO2021190369A1 (fr) * 2020-03-26 2021-09-30 黄海兵 Applicateur de médicament dans la cavité nasale, applicateur de médicament dans le sinus paranasal entier, applicateur de médicament nasopharyngien, et procédé d'administration de médicament

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5062423A (en) 1990-02-27 1991-11-05 Minnesota Mining And Manufacturing Company Equine aerosol drug delivery method and apparatus
EP0692273A1 (fr) 1994-06-17 1996-01-17 Trudell Medical Limited Cathéter comprenant un dispositif de nébulisation et son procédé de fabrication
WO2003000310A2 (fr) * 2001-06-12 2003-01-03 Optinose As Dispositifs d'administration nasale
US20060276552A1 (en) 2005-05-13 2006-12-07 Denise Barbut Methods and devices for non-invasive cerebral and systemic cooling
WO2012123819A1 (fr) * 2011-03-15 2012-09-20 Optinose As Et Al Administration nasale
EP3139985A1 (fr) * 2014-05-09 2017-03-15 Norton (Waterford) Limited Dispositif d'aérosol
CN106994205A (zh) 2017-04-13 2017-08-01 杜云飞 一种多功能鼻咽医用装置
WO2020197995A1 (fr) * 2019-03-28 2020-10-01 The Board Of Trustees Of The Leland Stanford Junior University Système d'administration par voie nasale de médicament
CN111388848A (zh) 2020-03-26 2020-07-10 乐恩(北京)医药技术有限公司 一种鼻咽部给药器和给药方法
WO2021190369A1 (fr) * 2020-03-26 2021-09-30 黄海兵 Applicateur de médicament dans la cavité nasale, applicateur de médicament dans le sinus paranasal entier, applicateur de médicament nasopharyngien, et procédé d'administration de médicament

Also Published As

Publication number Publication date
GB202201107D0 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US11413407B2 (en) Aerosol delivery device
RU2141351C1 (ru) Способ доставки лекарственного средства в дыхательную систему пациента, способ доставки лекарственного средства в одно или два легких пациента, которому не вставлена интубационная трубка, способ доставки аэрозоля лекарственного средства в легкие пациента, способ доставки лекарственного средства к разветвленному участку дыхательной системы пациента, катетер для доставки аэрозоля лекарственного средства в легкие пациента (варианты), катетерная система для доставки аэрозоля лекарственного средства в легкие пациента, катетерная система для доставки аэрозольной терапии в легкие пациента, дренажный катетер для использования в интубационной трубке и способ изготовления катетера для распыления жидкости с помощью газа
US8550073B2 (en) Nasal delivery
US5797390A (en) Nasal inhaler having a directed spray pattern
AU2016207776B2 (en) Respiratory interface
WO2003084591A1 (fr) Dispositifs nasaux
JP2009517184A (ja) 嗅覚部位に物質を送達するための鼻用送達装置
EP4008381B1 (fr) Dispositif de distribution d'aérosols
US20230285697A1 (en) Device for delivery of a compound to specific regions of the nasal cavity
WO2023146971A1 (fr) Dispositif d'administration d'un composé dans des régions précises de la cavité nasale
JP7213991B2 (ja) 経鼻薬送達器具
GB2403154A (en) Nasal inhaler with regulated gas stream
WO2023095019A1 (fr) Dispositif d'administration trachéale et cathéter de pulvérisation
AU740924B2 (en) Nebulizing catheter system and methods of use and manufacture
AU2008202441A1 (en) Nasal devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23706920

Country of ref document: EP

Kind code of ref document: A1